Related Experiment Video
Updated: Sep 14, 2025
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer
Mao Xiao1, Zhi-Yan Luo2, Ai-Ru Yu3
1Department of Respiratory Medicine, Second People's Hospital of Xindu Distrct, Chengdu 610501, Sichuan Province, China.
Background:
Pancreatic cancer (PC) is an aggressive malignancy. As a member of the BTN/BTNL family, BTNL9 has been identified as a tumor suppressor in breast cancer, lung adenocarcinoma, and colon cancer; however, its role and underlying mechanisms in PC remain to be elucidated.
Aim:
To investigate the role of BTNL9 in the pathogenesis and development of PC.
Methods:
The difference of BTNL9 expression in cancer and adjacent normal tissues was analyzed by RNA sequencing data from a public database and tissue microarray detection. The relationship between BTNL9 expression and the prognosis of patients was also studied. The effects of BTNL9 on proliferation, metastasis, and cell cycle of PC cells were investigated by phenotypic experiments. The mechanism was investigated by RNA sequencing, western blotting, and immunofluorescence detection.
Results:
The mRNA and protein levels of BTNL9 in PC tissues were downregulated compared with normal tissues. Based on survival data from The Cancer Genome Atlas and tissue microarray, BTNL9 was an independent influencing factor for overall survival, and its low expression predicted a shortened overall survival of patients. In vitro, BTNL9 could inhibit cell proliferation and metastasis in both PANC-1 and MIA PaCa-2 cells and induce cell cycle arrest in G2/M phases. Downregulation of BTNL9 could activate the cell cycle signaling pathway. Furthermore, overexpression of BTNL9 could significantly inhibit the expression of cell division cycle 20 (CDC20). Rescue experiments demonstrated that overexpression of CDC20 reversed the effect of BTNL9 on the proliferation, metastasis, and cell cycle of PC cells.
Conclusion:
The expression of BTNL9 was downregulated in PC, and it has the prediction ability for prognosis. Functionally, BTNL9 exerted an anti-cancer effect by suppressing downstream CDC20 expression in PC.
Insights
Butyrophilin-like 9 (BTNL9) is downregulated in pancreatic cancer (PC), acting as a tumor suppressor. Low BTNL9 expression predicts poor prognosis and inhibits PC cell proliferation and metastasis by downregulating CDC20.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic cancer (PC) is an aggressive malignancy with limited treatment options.
- Butyrophilin-like 9 (BTNL9) is a known tumor suppressor in other cancers, but its role in PC is unclear.
Purpose of the Study:
- To elucidate the role of BTNL9 in pancreatic cancer pathogenesis and development.
- To investigate the prognostic significance of BTNL9 in PC patients.
Main Methods:
- Analysis of BTNL9 expression in PC tissues versus normal tissues using RNA sequencing and tissue microarrays.
- In vitro studies assessing the impact of BTNL9 on PC cell proliferation, metastasis, and cell cycle.
- Mechanistic investigations involving RNA sequencing, western blotting, and immunofluorescence.
Main Results:
- BTNL9 expression (mRNA and protein) is significantly downregulated in PC tissues.
- Low BTNL9 expression is an independent predictor of shorter overall survival in PC patients.
- BTNL9 inhibits PC cell proliferation and metastasis, inducing G2/M cell cycle arrest, partly through suppression of CDC20.
Conclusions:
- BTNL9 is downregulated in pancreatic cancer and serves as a prognostic biomarker.
- BTNL9 functions as an anti-cancer agent in PC by inhibiting cell proliferation, metastasis, and cell cycle progression via suppression of CDC20.
More Related Videos
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...